CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 13.39: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
3.86BCNY576.23M · vs all stocks (USD)
Revenue (TTM)
235.69MCNY35.17M · vs all stocks (USD)
Profit Margin
-7.61%Beta
0.4900xvs all stocks
52-Week Change
-49.58%vs all stocks
Market Capitalization
3.86BCNY576.23M · vs all stocks (USD)
Enterprise Value
3.49BCNY521.33M · vs all stocks (USD)
Price to Sales (TTM)
16.38xPrice to Book (MRQ)
5.77xEnterprise to Revenue
14.82xGross Margin
20.04%Profit Margin
-7.61%Operating Margin
1.15%Return on Assets (TTM)
-0.73%Return on Equity (TTM)
-2.10%Revenue (TTM)
235.69MCNY35.17M · vs all stocks (USD)
Revenue per Share (TTM)
0.1830CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-25.20%Gross Profit (TTM)
49.90MCNY7.45M · vs all stocks (USD)
EBITDA (TTM)
20.40MCNY3.04M · vs all stocks (USD)
Net Income (TTM)
-17.94MCNY-2.68M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-25.23%Operating Cash Flow (TTM)
-21.72MCNY-3.24M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-62.14MCNY-9.27M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
137.13MCNYFY2025 · Dec 31, 2025Revenue
271.53MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
214.75MCNYFY2025 · Dec 31, 2025Gross Profit
56.79MCNYFY2025 · Dec 31, 2025Operating Income
-5.99MCNY-893.25K · vs all stocks (USD)
Pre-tax Income
-5.37MCNYFY2025 · Dec 31, 2025Income Tax Expense
-1.38MCNYFY2025 · Dec 31, 2025Net Income
-3.99MCNYFY2025 · Dec 31, 2025EBIT
-5.36MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
20.40MCNYFY2025 · Dec 31, 2025Research & Development
10.83MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
23.50MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.81MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
9.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.16KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0030CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0030CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.46BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.46BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-3.99MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-394.32KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-14.65MCNYFY2025 · Dec 31, 2025Free Cash Flow
-24.40MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
481.66MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-3.99MCNYFY2025 · Dec 31, 2025Other Non-cash Items
111.97KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
21.02MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-31.79MCNYFY2025 · Dec 31, 2025Capital Expenditures
-9.75MCNYFY2025 · Dec 31, 2025Purchase of Investments
-130.00MCNYFY2025 · Dec 31, 2025Sale of Investments
90.28MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-49.48MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
787.50KCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.30KCNYFY2025 · Dec 31, 2025Other Financing Charges
-26.58KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.25MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.29BSharesUpdated Sep 20, 2026Float Shares
894.26MSharesUpdated Sep 20, 2026% Held by Insiders
32.69%vs all stocks
% Held by Institutions
0.22%vs all stocks
Total Cash (MRQ)
508.22MCNY75.84M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3950CNYUpdated Sep 20, 2026Total Debt (MRQ)
1.18MCNY176.27K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0015xCurrent Ratio (MRQ)
5.90xBook Value per Share (MRQ)
0.5200CNYUpdated Sep 20, 2026Total Assets
984.18MCNY146.86M · vs all stocks (USD)
Total Current Assets
788.37MCNYFY2025 · Dec 31, 2025Total Liabilities
165.02MCNYFY2025 · Dec 31, 2025Total Non-current Assets
195.81MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
38.48MCNYFY2025 · Dec 31, 2025Total Current Liabilities
126.55MCNYFY2025 · Dec 31, 2025Cash
481.66MCNYFY2025 · Dec 31, 2025Cash Equivalents
23.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
504.87MCNYFY2025 · Dec 31, 2025Accounts Receivable
46.41MCNYFY2025 · Dec 31, 2025Inventory
170.58MCNYFY2025 · Dec 31, 2025Accounts Payable
112.02MCNYFY2025 · Dec 31, 2025Short-term Debt
787.50KCNYFY2025 · Dec 31, 2025Other Current Liabilities
138.79KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
36.51MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.29BCNYFY2025 · Dec 31, 2025Retained Earnings
-1.21BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
819.16MCNY122.23M · vs all stocks (USD)
52-Week Low
2.52CNYUpdated Sep 20, 202652-Week High
10.28CNYUpdated Sep 20, 202652-Week Change
-49.58%vs all stocks
Beta
0.4900xvs all stocks
50-Day MA
2.97CNYUpdated Sep 20, 2026200-Day MA
4.04CNYUpdated Sep 20, 2026Avg 10-Day Volume
24.72MSharesUpdated Sep 20, 2026Avg 30-Day Volume
34.08MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.0100CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 16.38Revenue Growth YoY: -0.25
Financial Health
Altman Z-Score 13.39: safe zoneNotable
Altman Z-Score: 13.39
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zeria Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ChemoCentryx Inc
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tilray Brands, Inc.
Tier 1ProductionApproval-Gated PipelineFlowAttention
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Orient Gene Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule